Product image of Brineura (Cerliponase Alfa) supplied by GNH India

Brineura

Active Ingredient:
Cerliponase Alfa
Origin:
EU

Brineura (Cerliponase Alfa)

Brineura (Cerliponase Alfa) is an enzyme replacement therapy used for a specific genetic disorder. This medication is administered via intracerebroventricular infusion and is designed to manage a rare condition affecting the central nervous system.

Manufacturer / TM Owner

Biomarin International Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • Brineura is primarily used for the treatment of a specific genetic disorder that leads to the accumulation of harmful substances in the brain. This medication is intended to help manage the progression of this condition by replacing the missing enzyme. Patients and healthcare providers often explore 'what is Brineura used for' to understand its role in enzyme replacement therapy.

Side Effects

  • Common effects of Brineura may include reactions at the injection site, such as pain, swelling, or fever. Some patients might experience headaches or nausea. These effects are generally monitored and managed by healthcare professionals during treatment.

Precautions & Warnings

  • Brineura should be administered under strict medical supervision due to its route of administration. Patients should be monitored for any signs of infection or adverse reactions. It is crucial to follow all safety guidelines provided by the healthcare provider to ensure safe and effective use.

Avoid Interactions

  • Brineura may interact with other medications, particularly those that affect the immune system or blood clotting. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions. Alcohol and certain supplements might also influence the effectiveness of Brineura.

Frequently Asked Questions

Brineura is used for the treatment of a specific genetic disorder that affects the central nervous system by replacing a missing enzyme.

Brineura is administered via intracerebroventricular infusion, which requires medical supervision and specialized equipment.

Common side effects may include reactions at the injection site, such as pain, swelling, or fever, as well as headaches or nausea.

Brineura is manufactured by Biomarin International Limited, a company based in the EU.

The safety of Brineura for long-term use should be discussed with a healthcare provider, who can monitor the patient's response and adjust treatment as needed.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated:

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cerliponase Alfa

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT